No Data
Earnings Preview: PTCT to Report Financial Results Post-market on February 27
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics Receives Priority Review for Its Nervous System Disorder Treatment
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $60
Express News | The FDA Has Accepted PTC Therapeutics' New Drug Application For Vatiquinone For Children And Adults Living With Friedreich's Ataxia, Under Priority Review And Assigned A Prescription Drug User Fee Act Target Action Date Of August 19
Express News | PTC Therapeutics Inc - Pdufa Target Action Date of Aug. 19, 2025
